Gonal-F: profile and news

Serono's Gonal-F Sales Confirm Downtrend  Feb 6, 2006
0922 GMT [Dow Jones] Serono's (SRA) 4Q numbers are disappointing, and especially the sales for its fertility drug Gonal-F confirm earlier downtrend, says ... - New Ratings

Seronons 2005 Adjusted(i) EPS Increased by 34.6%  Feb 5, 2006
In 2005, sales of Gonal-f(R) decreased by 4.5% (-5.2% in local currencies) to $547.0m (2004: $572.7m) and by 11.7% (-9.0% in local currencies) to $133.5m in ... - MSN Money

Serono 4th-Quarter Profit Lags Estimates, Sales Drop (Update1)  Feb 5, 2006
Demand for Serono's best-selling treatments, the multiple sclerosis therapy Rebif and fertility drug Gonal-f, fell short of forecasts. ... - Bloomberg

Serono 4th-Quarter Net Misses Estimates, Sales Drop (Update4)  Feb 6, 2006
Shares of Serono, which sells the multiple sclerosis therapy Rebif and fertility drug Gonal-f, fell to their lowest level since Nov. ... - Bloomberg

Serono: On the Block and On the Clock  Feb 9, 2006
The company had good initial success with products like Rebif for multiple sclerosis and Gonal-f for infertility but has found it difficult to build on that ... - Motley Fool

Flat sales in Q4 for Serono; no word on buyer  Feb 6, 2006
...second quarter in a row at $605 million, as growth slowed for its multiple sclerosis product Rebif and sales of its fertility treatment Gonal F continued to ... - Pharma Times (subscription),

Serono sales, profits miss forecasts, mum on M&A  Feb 6, 2006
...flat in the fourth quarter at $604.5 million, as multiple sclerosis drug Rebif posted an 8.2 percent sales increase and sales of fertility drug Gonal-F fell by ... - ABC News

UPDATE 2-Serono sales, profits miss forecasts, mum on M&A  Feb 5, 2006
...the fourth quarter at $604.5 million, as a surge in demand for multiple sclerosis drug Rebif appeared to cool off and sales of fertility drug Gonal-F fell by ... - Reuters

The Fertility Gamble  Feb 20, 2006
That drug, Clomid, didn’t work. Candy began getting injections of Gonal -F, to increase the number of eggs available for fertilization. ... - Press of Atlantic City,

Serono sales, profits miss forecasts, mum on M&A  Feb 5, 2006
...biggest biotech firm were flat in the fourth-quarter at $604.5 million, as Rebif's surge appeared to cool off and sales of fertility drug Gonal-F fell by 11.7 ... - Reuters

Serono 4Q Data Is Light On Revenue-JP Morgan  Feb 6, 2006
0755 GMT [Dow Jones] Serono (SRA) 4Q earnings are light on revenues, says JP Morgan, because of Rebif and Gonal-f missing views. ... - New Ratings

Swiss shares close flat tracking Wall Street; pharmas under ...  Feb 6, 2006
Morgan said normalised Q4 net income was in line with expectations, but that product sales -- most notably flagship products Rebif and Gonal-F -- were weaker ... - Forbes

Movers: Lafarge makes offer to acquire its US unit  Feb 6, 2006
Shares of Serono, which sells the multiple sclerosis therapy Rebif and fertility drug Gonal-f, fell when the company said it hired Goldman Sachs to explore a ... - International Herald Tribune,

Serono: On the Block and On the Clock  09 Feb 2006
The company had good initial success with products like Rebif for multiple sclerosis and Gonal-f for infertility but has found it difficult to build on that ... - Motley Fool

Serono's Gonal-F Sales Confirm Downtrend  Feb 6, 2006
0922 GMT [Dow Jones] Serono's (SRA) 4Q numbers are disappointing, and especially the sales for its fertility drug Gonal-F confirm earlier downtrend, says ... - New Ratings

Serono's Gonal-f against male hypogonadism approved in Japan  Jan 23, 2006
ZURICH (AFX) - Serono SA said the Japanese Ministry of Health has approved Gonal-f 75 IU and Gonal-f 150 IU subcutaneous injection in conjunction with Profasi ... - Forbes

Serono's Gonal-f Approved in Japan for the Treatment of Male ...  Jan 24, 2006
GENEVA, SWITZERLAND -- January 24, 2006 -- Serono announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Gonal-f® 75 IU and ... - DG News

Serono's Gonal-f(R) Approved in Japan for the Treatment of Male ...  Jan 23, 2006
FirstCall/ -- Serono (virt-x: SEO and NYSE: SRA) announced today that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Gonal-f® 75 IU ... - Yahoo! News (press release)

Seronons 2005 Adjusted(i) EPS Increased by 34.6%  Feb 5, 2006
In 2005, sales of Gonal-f(R) decreased by 4.5% (-5.2% in local currencies) to $547.0m (2004: $572.7m) and by 11.7% (-9.0% in local currencies) to $133.5m in ... - MSN Money

Serono 4th-Quarter Profit Lags Estimates, Sales Drop (Update1)  Feb 5, 2006
Demand for Serono's best-selling treatments, the multiple sclerosis therapy Rebif and fertility drug Gonal-f, fell short of forecasts. ... - Bloomberg

Serono 4th-Quarter Net Misses Estimates, Sales Drop (Update4)  Feb 6, 2006
Shares of Serono, which sells the multiple sclerosis therapy Rebif and fertility drug Gonal-f, fell to their lowest level since Nov. ... - Bloomberg

Serono's Gonal-f Approved in Japan for the Treatment of Male ...  Jan 24, 2006
January 24, 2006 /PRNewswire-FirstCall/ -- Serono announced today that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Gonal-f(R) 75 IU ... - PharmaLive.com (press release),

Flat sales in Q4 for Serono; no word on buyer  Feb 6, 2006
...second quarter in a row at $605 million, as growth slowed for its multiple sclerosis product Rebif and sales of its fertility treatment Gonal F continued to ... - Pharma Times (subscription),

Serono sales, profits miss forecasts, mum on M&A  Feb 6, 2006
...flat in the fourth quarter at $604.5 million, as multiple sclerosis drug Rebif posted an 8.2 percent sales increase and sales of fertility drug Gonal-F fell by ... - ABC News

UPDATE 2-Serono sales, profits miss forecasts, mum on M&A  Feb 5, 2006
...the fourth quarter at $604.5 million, as a surge in demand for multiple sclerosis drug Rebif appeared to cool off and sales of fertility drug Gonal-F fell by ... - Reuters

Serono sales, profits miss forecasts, mum on M&A  Feb 5, 2006
...biggest biotech firm were flat in the fourth-quarter at $604.5 million, as Rebif's surge appeared to cool off and sales of fertility drug Gonal-F fell by 11.7 ... - Reuters

Serono 4Q Data Is Light On Revenue-JP Morgan  Feb 6, 2006
0755 GMT [Dow Jones] Serono (SRA) 4Q earnings are light on revenues, says JP Morgan, because of Rebif and Gonal-f missing views. ... - New Ratings

Swiss shares close flat tracking Wall Street; pharmas under ...  Feb 6, 2006
Morgan said normalised Q4 net income was in line with expectations, but that product sales -- most notably flagship products Rebif and Gonal-F -- were weaker ... - Forbes

Movers: Lafarge makes offer to acquire its US unit  Feb 6, 2006
Shares of Serono, which sells the multiple sclerosis therapy Rebif and fertility drug Gonal-f, fell when the company said it hired Goldman Sachs to explore a ... - International Herald Tribune,

Serono to market fertility treatment in Japan  Jan 25, 2006
By Staff Writer. Swiss biotech Serono has had its Gonal-f products, aimed at treating male gonadal dysfunction, approved for sale in Japan. ... - Pharmaceutical Business Review

Dead kangaroos don’t bounce, do they?  Jan 14, 2006
A buyer would also get the Gonal-F fertility treatment, experimental drugs for cancer and inflammatory illnesses as well as its production capacity. ... - Business Online,

Latest Developments In Infertility Treatment  Jan 28, 2006
...both FSH (follicle stimulating hormone) and hCG-driven (human chorionic gonadotrophon) LH-activity (luteinizing hormone) and Gonal-F (recombinant FSH only) in ... - Medical News Today (press release),

Serono Completes Second Phase III Trial of its Proprietary ...  Jan 8, 2006
The Company has eight biotechnology products, Rebif®, Gonal-f®, Luveris®, Ovidrel® /Ovitrelle®, Serostim®, Saizen®, Zorbtive(TM) and Raptiva®. ... - Yahoo! News (press release)

Serono Completes Second Phase III Trial of its Proprietary ...  Jan 8, 2006
The Company has eight biotechnology products, Rebif(R), Gonal-f(R), Luveris(R), Ovidrel(R) /Ovitrelle(R), Serostim(R), Saizen(R), Zorbtive(TM) and Raptiva(R ... - PR Newswire (press release),

Novartis, Glaxo Close to Bids for Serono, People Say (Update2)  Jan 11, 2006
A buyer would also get the Gonal-F fertility treatment, experimental drugs for cancer and inflammatory illnesses and production capacity. ... - Bloomberg

On the Move: Serono, Royal Dutch Shell, DaimlerChrysler  Jan 24, 2006
...minute. The article clearly offset news that the company's Gonal-f received approval in Japan. CS GROUP was down CHF0.35 to CHF71.80. ... - BusinessWeek

(PRN) - Following Is a Test Release ... [+]  Jan 23, 2006
...(PRN) - Serono's Gonal-f(R) Approved in Japan for the Treatment of Male Hypogonadotropic Hypogonadism ... [+. PRN) - Argos Selects ... - Bolsamania.com,

In vitro field facing slowdown  Nov 13, 2005
Erica Whittaker, a Merrill Lynch analyst, projects annual growth rates for sales of Gonal-F, one of the main IVF drugs, of about 5 percent in the near future. ... - Boston Globe,

Goldman Sachs Retained to Explore Strategic Alternatives  Nov 8, 2005
The Company has eight biotechnology products, Rebif(R), Gonal-f(R), Luveris(R), Ovidrel(R )/Ovitrelle(R), Serostim(R), Saizen(R), Zorbtive(TM) and Raptiva(R ... - PR Newswire (press release),

Goldman Sachs Retained to Explore Strategic Alternatives  Nov 8, 2005
The Company has eight biotechnology products, Rebif®, Gonal-f®, Luveris®, Ovidrel(R )/Ovitrelle®, Serostim®, Saizen®, Zorbtive(TM) and Raptiva®. ... - Yahoo! News (press release)

Serono Ex-US Rebif Sales Disappoint  Oct 25, 2005
0716 GMT [Dow Jones] Serono (SRA) 3Q results were a little disappointing in terms of Rebif ex-US performance and continued weakness in Gonal-F, but owing to ... - New Ratings

Serono Has Costs Well Under Control - CSFB  Oct 25, 2005
0749 GMT [Dow Jones] Serono's (SRA) 3Q top line results are disappointing, says CSFB, especially ex-US Rebif and Gonal-F sales, which need to be examined in ... - New Ratings

Swiss shares close higher led by luxury goods stocks, banks, Roche ...  Oct 25, 2005
UBS said sales were below its estimate, with sales of MS drug Rebif slightly below expectations and Gonal-f continuing to suffer from competition. ... - Forbes

Serono Q3 net beats expectations but revenues weak UPDATE  Oct 24, 2005
Sales of its second most important drug, infertility treatment Gonal-f, disappointed even more, falling 6.6 pct in local currencies to 125.6 mln usd. ... - Forbes

Updates, advisories and surprises  Oct 25, 2005
...$638 million. Product sales rose 10.3%, with Rebif sales up 19.8% to $316 million while Gonal-f fell 5.8% to $126 million. Adjusted ... - Investor's Business Daily (subscription)

Schweizer Serono geht in USA einkaufen  Oct 26, 2005
The Company has eight biotechnology products, Rebif?, Gonal-f?, Luveris?, Ovidrel?/Ovitrelle?, Serostim?, Saizen?, Zorbtive(TM) and Raptiva?. ... - Vdbiol,

Serono relies on Rebif to boost 3Q  Oct 25, 2005
271.8m). Sales of GONAL-f decreased by 5.8 per cent, or 6.6 per cent in local currencies, to $125.6m (Q3 2004: $133.3m). Saizen ... - Drug Researcher.com,

EARNINGS PREVIEW: Serono 3Q Net Pft Seen -17% at $135M  Oct 21, 2005
Products sales are seen 16% higher at $600M. Analysts will focus on sales of Rebif, and the company's second-best selling product, Gonal-F. Report is due ... - New Ratings

Serono: Data And Safety Monitoring Board Recommends ...  Oct 3, 2005
The Company has eight biotechnology products, Rebif®, Gonal-f®, Luveris®, Ovidrel® /Ovitrelle®, Serostim®, Saizen®, Zorbtive(TM) and Raptiva®. ... - Yahoo! News (press release)

Data and Safety Monitoring Board Recommends Discontinuation of ...  Oct 3, 2005
The Company has eightbiotechnology products, Rebif(R), Gonal-f(R), Luveris(R),Ovidrel(R)/Ovitrelle(R), Serostim(R), Saizen(R), Zorbtive(TM) andRaptiva(R). In ... - Finanzen.net,

Data and Safety Monitoring Board Recommends Discontinuation of ...  Oct 4, 2005
The Company has eight biotechnology products, Rebif(R), Gonal-f(R), Luveris(R), Ovidrel(R)/Ovitrelle(R), Serostim(R), Saizen(R), Zorbtive(TM) and Raptiva(R ... - PharmaLive.com (press release),

Serono: Data And Safety Monitoring Board Recommends ...  Oct 3, 2005
The Company has eight biotechnology products, Rebif(R), Gonal-f(R), Luveris(R), Ovidrel(R) /Ovitrelle(R), Serostim(R), Saizen(R), Zorbtive(TM) and Raptiva(R ... - PR Newswire (press release),

Serono: Data And Safety Monitoring Board Recommends ...  Oct 3, 2005
The Company has eight biotechnology products, Rebif®, Gonal-f®, Luveris®, Ovidrel® /Ovitrelle®, Serostim®, Saizen®, Zorbtive(TM) and Raptiva®. ... - Yahoo! News (press release)

Fertility LifeLines(TM) Offers Single Destination for Access to ...  Aug 10, 2005
...for every stage of the reproductive cycle and recombinant versions of three hormones used in the treatment of infertility, including the Gonal-f(R) RFF Pen ... - PR Newswire (press release),

Serono and Genmab Announce Global Development and ...  Aug 17, 2005
The Company has eight biotechnology products, Rebif®, Gonal-f®, Luveris®, Ovidrel(R )/Ovitrelle®, Serostim®, Saizen®, Zorbtive(TM) and Raptiva®. ... - Yahoo News (press release)

Serono and Genmab Announce Global Development and ...  Aug 18, 2005
The Company has eight biotechnology products, Rebif(R), Gonal-f(R), Luveris(R), Ovidrel(R )/Ovitrelle(R), Serostim(R), Saizen(R), Zorbtive(TM) and Raptiva(R ... - PharmaLive.com (press release),

Is There Still Hope After 40?  Aug 24, 2005
Human menopausal gonadotropins, such as Pergonal, Humegon, and Repronex, were also included in the cycles, as well as an FSH therapy like Follistim or Gonal-F. ... - Fertility Neighborhood,

Westchester Druggist Held in $4 Million Fraud  Aug 4, 2005
At least three customers were also cheated of their supplies of a drug called Gonal F, used to treat infertility, Ms. Pirro said. ... - New York Times

Serono Delivers Strong Second Quarter Results  Jul 19, 2005
Gonal-f® sales were stable (-0.7% or -2.8% in local currencies) at $149.9m (Q2 2004: $150.9m). Gonal-f® delivered double-digit growth outside of the US due ... - Yahoo News (press release)

Serono Welcomes Positive Ratings From Credit Agencies  Jul 13, 2005
The Company has eight biotechnology products, Rebif(R), Gonal-f(R), Luveris(R), Ovidrel(R)/Ovitrelle(R), Serostim(R), Saizen(R), Zorbtive(TM) and Raptiva(R ... - Black Enterprise

Serono's Rebif Excels As Expected  Jul 20, 2005
However, warns that drug Gonal-F didn't perform as forecast. Still, bank keeps buy rating, CHF90 price target. Shares +2.2% at CHF861. (GOM). ... - New Ratings